A method of establishing a quantitative measure of contrast enhancement in contrast medical imaging through computer analysis of baseline and enhanced images allows statistical comparison of protocols and imaging parameters from routine hospital operations to enhance and evaluate such protocols and parameters.

The disclosure relates to a method for creating a three-dimensional digital subtraction angiography image of a vascular system of a patient. The method includes: providing a first reconstructed three-dimensional filling image which was acquired during at least partial contrast agent filling of the vascular system with a first contrast agent; providing a second reconstructed three-dimensional filling image which was acquired during at least partial contrast agent filling of the vascular system with a second contrast agent; and subtracting the first three-dimensional filling image from the second three-dimensional filling image so that a three-dimensional subtraction angiography image is produced, wherein the first contrast agent and the second contrast agent differ in that one of the two causes increased X-ray absorption and the other causes reduced X-ray absorption relative to a vascular system without contrast agent.

The present invention aims to dramatically increase the effect of hepatic arterial chemoembolization by developing human serum albumin-based nanoparticles, which are bioproteins that effectively carry Adriamycin in place of Adriamycin, an anticancer agent used in hepatic arterial chemoembolization. The human serum albumin nanoparticles carrying the Adriamycin not only intensively infiltrate the drug effectively into the cells but also have a synergistic effect that can induce a long-term therapeutic effect by utilizing the effect of continuous drug release from the particles.

The present invention relates to injectable, thermosensitive hydrogel compositions comprising linezolid for relieving and/or treating chronic low back pain (CLBP).

This invention relates to novel contrast agents for detection of diseases by using any or both or all of CT, SPECT and PET scans. Previously, there was no way to use these novel contrast agents for imaging and early detection of neurodegenerative diseases, multiple sclerosis disease, concussion, and traumatic brain injury. Also, previously, there was no way to use Computed Tomography (CT) imaging to early detect and map the neurodegenerative diseases. Embodiments of the present invention use a novel contrast agent is disclosed for early detection of diseases by using any or both or all of CT, SPECT and PET. Also, these novel contrast agents can be used for detection of amyloid beta, tau protein, alpha-synuclein protein, and aggregation proteins in neurodegenerative diseases and inflammation in many diseases such as neurodegenerative diseases, cancer and other inflammatory diseases, blood brain barrier leakage or break down, aggressive cancer tissue, brain activation in neurodegenerative diseases and other diseases, and hypoxia in tissue. Also, these novel contrast agents increase there binding in diseases compared to healthy subjects, therefore induce higher contrast in diseases such as in neurodegenerative diseases, cancer and other inflammatory diseases, blood brain barrier leakage or break down, aggressive cancer tissue, brain activation in neurodegenerative diseases and other diseases, and hypoxic tissue.

Various embodiments are described herein for a system and a method for identifying a region of interest in tissue using mass spectrometry. An agent administration component can be provided to administer an exogenous agent to the tissue. A sampling unit can also be provided to acquire a sample from the tissue. The sample can then be provided to a high sensitivity analysis platform, such as a mass analyzer, to analyze the sample and determine a distribution of the exogenous agent or a by-product of the exogenous agent within the tissue based on the analysis. The analysis platform can then identify the region of interest based on the distribution of the exogenous agent or the distribution of the by-product.

Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and/or energy are effective to injury or damage the tissues to have a benefit of symptom relive.

Disclosed herein is an injectable anticancer composition for local administration, which contains a suspension of quinine hydrochloride. The anticancer composition for local administration according to the present invention shows an IC.sub.50 value against MKN-45 cells, which is about 10 times lower than Paclitaxel, as determined by an MTT assay in vitro, suggesting that the anticancer composition has an excellent cytotoxic effect. The anticancer composition can be administered as a safe anticancer agent in clinical applications, and also shows an anticancer effect by inducing the necrosis and detachment of solid cancer cells. Particularly, the anticancer composition has an anticancer mechanism by which the composition acts locally in a tumor tissue administered with the composition and shows a rapid antitumor effect (1-2 weeks after administration).

The present invention provides compositions, and related kits and methods, for formation of hydrogels. The compositions comprise one or more chemically crosslinkable agents dissolved in an aqueous solution to form a precursor solution. The chemically crosslinkable agents useful in the present invention are selected from polymers modified with a molecule selected from acrylate, maleimide, vinylsulfone, N-hydroxysuccinimide, aldehyde, ketone, carbodiimide, carbonate, iodoacetyl, mercaptonicotinamide, quinone, thiol, amine, and combinations thereof. The precursor solution is characterized as being in an aqueous form at a non-physiologic physical-chemical condition and undergoing gelation when in contact with another fluid or body at a physiologic physical-chemical condition.

This document provides materials and methods for permanent arterial embolization and/or enhanced vascular healing. For example, materials and methods for using bioactive tissue derived nanocomposite hydrogels to enhance vascular healing are provided.